Your browser is no longer supported. Please, upgrade your browser.
SNY Sanofi daily Stock Chart
Index- P/E22.72 EPS (ttm)1.86 Insider Own16.40% Shs Outstand2.55B Perf Week1.51%
Market Cap108.04B Forward P/E13.37 EPS next Y3.17 Insider Trans0.00% Shs Float2.30B Perf Month5.01%
Income4.89B PEG3.20 EPS next Q0.75 Inst Own9.70% Short Float0.20% Perf Quarter-0.25%
Sales38.11B P/S2.84 EPS this Y4.10% Inst Trans-0.02% Short Ratio1.97 Perf Half Y6.39%
Book/sh24.55 P/B1.72 EPS next Y0.16% ROA- Target Price52.00 Perf Year-17.39%
Cash/sh- P/C- EPS next 5Y7.10% ROE- 52W Range36.11 - 52.76 Perf YTD3.38%
Dividend1.66 P/FCF- EPS past 5Y-4.40% ROI6.50% 52W High-20.16% Beta0.98
Dividend %3.92% Quick Ratio- Sales past 5Y0.50% Gross Margin68.80% 52W Low16.65% ATR0.77
Employees115631 Current Ratio- Sales Q/Q-3.60% Oper. Margin- RSI (14)57.30 Volatility0.91% 1.57%
OptionableYes Debt/Eq- EPS Q/Q4.60% Profit Margin- Rel Volume2.70 Prev Close42.31
ShortableYes LT Debt/Eq- EarningsJul 29 BMO Payout- Avg Volume2.32M Price42.12
Recom2.30 SMA202.01% SMA503.96% SMA2002.76% Volume436,175 Change-0.44%
May-03-16Downgrade HSBC Securities Buy → Hold
Dec-10-15Downgrade Exane BNP Paribas Neutral → Underperform
Dec-01-15Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-09-15Downgrade Bernstein Outperform → Mkt Perform
Oct-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-22-15Upgrade Citigroup Sell → Neutral
Apr-15-15Initiated Societe Generale Buy
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
Aug-28-09Upgrade JP Morgan Neutral → Overweight
Jun-29-09Downgrade JP Morgan Overweight → Neutral
May-28-09Upgrade Citigroup Hold → Buy
Apr-30-09Upgrade JP Morgan Neutral → Overweight
Mar-23-09Upgrade Jefferies & Co Underperform → Hold
Mar-17-09Initiated Credit Suisse Outperform
Feb-19-09Upgrade JP Morgan Underweight → Neutral
Jan-26-09Initiated Jefferies & Co Underperform
Nov-07-08Downgrade UBS Neutral → Sell
Jul-23-16 07:21AM  Mylans EpiPen price increases are Valeant-like in size, Shkreli-like in approach at MarketWatch
Jul-22-16 04:11PM  Eli Lilly, J&J, Novo Battle Diabetes -- And Each Other
01:07PM  What Are Lillys 2Q16 Estimates and Expectations for Elanco?
12:13PM  Six Major Biotech Acquisitions You Could See in 2016 (Part 2) at Forbes
Jul-21-16 05:00PM  Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal
04:41PM  How Analysts Think Investors Should Play Vertex Pharmaceuticals
02:58PM  Investors Scour Big Pharma M&A Scene for Next Big Takeover
Jul-20-16 12:03PM  Why I Bought Shares of Regeneron Pharmaceuticals Inc. Last Week at Motley Fool
11:00AM  VBIV: A Differentiated Immunology Company With Multiple Near Term Value Drivers
Jul-19-16 11:41AM  EU mergers and takeovers (July 19) Reuters
Jul-15-16 09:36AM  The Most Popular French Stocks Among Hedge Funds at Insider Monkey
Jul-14-16 04:11PM  The UN's War On Medical Innovations at Forbes
Jul-13-16 04:31PM  Here's Why Regeneron Pharmaceuticals, Inc. Dropped Another 12% in June at Motley Fool
03:51PM  Why Did Jazz Fall after Celator Acquisition Announcement?
09:05AM  Regenerons Dupilumab: How Much Potential Does It Hold?
Jul-12-16 05:06PM  These Four Drugs Were Withdrawn by the CHMP in June
03:59PM  Better Buy: Medivation, Inc. vs. Inovio Pharmaceuticals, Inc. at Motley Fool
02:44PM  Why Relypsa Stock Is Ripping
10:20AM  Amgen's Repatha Gains FDA Approval for New Dosing Option
09:27AM  Instant Analysis: Amgen's Latest Approval Raises the Bar Yet Again on Regeneron Pharmaceuticals Inc and Sanofi SA (ADR) at Motley Fool
Jul-09-16 10:40AM  Why BioMarin's Shares Tumbled 11% in June at Motley Fool
Jul-08-16 04:10PM  Icagen, out from under Pfizer's umbrella, raises $1.5 million at
08:25AM  San Antonio cancer therapeutics company taps familiar expertise at
Jul-07-16 05:07PM  Sanofi Pasteur (SNY) Partners With Walter Reed Army Institute to Create Zika Vaccine
04:06PM  Roche Said To Mull BioMarin Buyout, Driving Up Stock
03:43PM  White House urges Zika funding
02:36PM  Medivation Overplays a Risky Hand at Bloomberg
11:21AM  Medivation: Why Would They Even Consider Selling? at
10:48AM  This $10 billion drugmaker is the hottest thing in the industry and it knows it
10:09AM  Sanofi Starts Olipudase Alfa Study, Praluent Ok'd in Japan
10:05AM  BioMarin Pharmaceutical shares rise on talk of a takeover from Roche at CNBC
09:40AM  Stocks Open Higher; WhiteWave Soars On Danone Deal
08:23AM  Medivation Tries to Prove Its Worth
Jul-06-16 07:50PM  Buyout target Medivation says cancer drug could be "best in class"
05:33PM  Cancer drug discovered by UCLA sets off takeover fight among biotech companies at Los Angeles Times
02:37PM  Sanofi Plays HardballAnd Loses at Bloomberg
01:51PM  [$$] Medivation confident drugs pipeline will win over suitors at Financial Times
09:45AM  Do Confidentiality Agreements Signal an Impending Medivation Acquisition? at 24/7 Wall St.
09:36AM  Medivation (MDVN) Stock Up on Potential Sanofi Deal
09:11AM  Blog Coverage Biotech Major Medivation Open to Takeover Talks
08:44AM  Medivation Shares Spike as Company Opens Door to Full-Fledged Auction
08:40AM  Morning Movers: American Airlines Tumbles on Downgrade; Tesla Drops at
08:00AM  Sanofi Genzyme Begins Pivotal Phase 2/3 Trial of Olipudase Alfa for Adult Patients with Acid Sphingomyelinase Deficiency Business Wire
06:10AM  July 6 Premarket Briefing: 10 Things You Should Know
05:20AM  Sanofi partners US Army on Zika vaccine AAP
04:04AM  France's Sanofi partners U.S. Army to speed up Zika vaccine
01:08AM  Sanofi signs research deal for a Zika vaccine with Pentagon
01:05AM  [$$] Medivation Opens Door to Takeover Talks With Sanofi at The Wall Street Journal
01:04AM  Sanofi Teams Up With U.S. Army on Zika Vaccine at The Wall Street Journal
01:00AM  Sanofi Teams Up With U.S. Army on Zika Vaccine at The Wall Street Journal
01:00AM  Sanofi Teams With U.S. Military on Zika Vaccine Development at Bloomberg
Jul-05-16 06:54PM  Sanofi, Pfizer, Celgene may each pursue Medivation takeover at MarketWatch
06:21PM  [$$] Medivation Opens Door to Takeover Talks With Sanofi at The Wall Street Journal
05:59PM  An Auction Process Could Be on Medivation's Horizon
05:52PM  Medivation officially rejects latest Sanofi offer, may field more bids at MarketWatch
05:51PM  [$$] Medivation agrees to $10bn takeover talks at Financial Times
05:30PM  Medivation Agrees To Work With Sanofi After Nixing Higher Bid
05:20PM  Medivation agrees to open its books to Sanofi Reuters
04:25PM  Medivation Enters Talks With Sanofi, Others After Raised Bid at Bloomberg
03:29PM  Exclusive: Medivation discusses potential sale to Sanofi - sources Reuters
08:00AM  Saskatchewan includes LEMTRADA® (alemtuzumab) on MS Drugs Program for eligible patients CNW Group
01:00AM  Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in Japan PR Newswire
Jul-01-16 01:33PM  Sony Walkman Turns 37, Generation X Gets Nostalgic at Forbes
10:02AM  Here's Why Regeneron Pharmaceuticals Inc Is Down 35% This Year at Motley Fool
Jun-30-16 04:06PM  What Are Analysts Thinking about Novo Nordisk?
03:07PM  What the CHMP Just Recommended for Alkems Riluzole Alkem
11:01AM  [$$] Who Will Acquire Medivation? at
Jun-29-16 05:06PM  What Tesaro's Cancer Drug Success Means for Medivation
03:04PM  Stocks Higher As Banks, Oil Stocks Keep Bouncing
01:15PM  Esperion Therapeutics Inc Sinks After FDA Says, "Ask Us in 2019" at Motley Fool
12:40PM  Deal of the Week: Why Pharmaceutical Companies Face an Existential M&A Crisis at Bloomberg
11:25AM  2016s Top 10 Dividend Stocks at Motley Fool
09:07AM  Why Market Share for Novo Nordisks Tresiba Is Set to Grow
Jun-28-16 02:30PM  Sanofi Agrees to $25.1B Asset Swap (SNY) at Investopedia
09:46AM  Faber Report: M&A updates
09:09AM  Could Novo Nordisks 2016 Earnings Impress Wall Street?
Jun-27-16 12:23PM  Novo Nordisks Premium Valuation Based on Price-to-Earnings
11:52AM  As Old Bestsellers Plateau, a Look at 4 Next Generation Diabetes Drugs at Insider Monkey
08:15AM  Sanofi Inks Deal to Swap Business with Boehringer Ingelheim
04:51AM  Sanofi to Exit Animal Care in $25 Billion Asset Swap With Boehringer
01:36AM  Sanofi, Boehringer Ingelheim Agree to $25 Billion Asset Swap
Jun-25-16 12:05PM  How Was Roches Operational Performance in 2Q16?
Jun-24-16 05:00PM  MannKind Will Market Afrezza Better Than Sanofi Ever Did at Forbes -6.65%
02:19PM  Glass Lewis urges Medivation shareholders to support current board
10:02AM  MannKind Corp. Shares Are Down 28.3% So Far This Year. Here's Why. at Motley Fool
Jun-23-16 05:01PM  Sanofi's Likely Sweetener for Medivation Panned
09:24AM  $18,543 Invested in This Biotech a Decade Ago Is Now Worth $1 Million at Motley Fool
07:56AM  New Four-Strain Influenza Vaccine, VaxigripTetra, Regulatory Dossier from Sanofi Pasteur Now Approved in Europe PR Newswire
Jun-22-16 11:05PM  Sanofi Pasteur Dengue Vaccine Approved in Costa Rica PR Newswire
01:46PM  Sanofi Said to Consider Adding Future Payments to Medivation Bid at Bloomberg
12:20PM  The Top Four Diabetes Best Sellers and One Oral Insulin Pill That May Threaten Them All at Insider Monkey
07:23AM  Warren Buffett's Favorite High-Yield Dividend Stock at Motley Fool
Jun-21-16 05:40PM  Why Biogen Inc. Is Down 22.5% In 2016 at Motley Fool
03:03PM  7 Pharmaceutical Stocks With Dividends Yielding More Than 3% at Motley Fool
01:06PM  [$$] Inovio Zika Vaccine Clear for Human Study at
09:05AM  How Inovio Pharmaceuticals Is Leading the Zika Vaccine Race at Motley Fool
Jun-20-16 08:57AM  Biotech stocks are in for more election trouble on drug pricing at MarketWatch
05:25AM  BioMed Realty exec on why Kendall Square lab space is still in such demand at
05:00AM  Visium Insider-Trading Scheme Brought Down by Tip on Mismarking
05:00AM  Visium Insider-Trading Scheme Brought Down by Mismarking Tip at Bloomberg
Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. It offers Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; Toujeo, an insulin glargine; and Afrezza, an inhaled insulin. The company also provides Praluent, a human monoclonal antibody; and Multaq, a multichannel blocker with anti-arrhythmic properties. In addition, it offers Cerezyme, an enzyme replacement therapy to treat gaucher disease; cerdelga, an oral therapy for Gaucher disease Type 1; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis Type 1, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for breast, prostate, gastric, lungs, and head and neck cancer treatment; Eloxatin for the treatment of stage III colon cancer; Thymoglobulin to treat acute rejection; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix/Iscover for atherothrombosis and acute coronary syndrome; Lovenox/Clexane for the treatment of venous thromboembolism; Aprovel/Avapro/Karvea for hypertension and nephropathy; Renagel/Renvela to treat chronic kidney disease; Allegra/Telfast to treat seasonal allergic rhinitis and uncomplicated hives; Stilnox/Ambien/Myslee for insomnia treatment; and Synvisc/Synvisc-One for the treatment of osteoarthritis pain. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerJun 14Buy363.8664,73123,552,85923,418,396Jun 16 05:47 PM
Sanofi10% OwnerFeb 17Buy393.7180,00031,496,72823,353,665Feb 18 05:45 PM
Sanofi10% OwnerFeb 16Buy391.2381,15731,751,18223,273,665Feb 18 05:45 PM
Sanofi10% OwnerJan 12Buy465.0483,93839,034,66023,192,508Jan 14 05:46 PM
Sanofi10% OwnerNov 03Buy10.00900,0009,000,0003,218,899Nov 05 02:37 PM
Sanofi10% OwnerOct 06Buy472.3311,0405,214,51923,108,570Oct 08 05:50 PM
Sanofi10% OwnerOct 06Buy459.7180,53837,024,19723,097,530Oct 08 05:45 PM
Sanofi10% OwnerJul 27Buy537.4810,6395,718,27222,869,783Jul 29 05:46 PM